Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Becaplermin.

J A Balfour1, S Noble

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|November 23, 2007
PubMed
Summary
This summary is machine-generated.

Becaplermin, a recombinant human platelet-derived growth factor B-chain homodimer (rh-PDGF-BB), effectively treats diabetic neuropathic and pressure ulcers. This topical therapy accelerates wound healing with minimal systemic absorption and good tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methods for think-aloud interviews in health-related resource-use research: the PECUNIA RUM instrument.

Expert review of pharmacoeconomics & outcomes research·2023
Same author

The Rise of Supportive Oncology: A Revolution in Cancer Care.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

Proper understanding of recurrent stress urinary incontinence treatment in women (PURSUIT): a randomised controlled trial of endoscopic and surgical treatment.

Trials·2022
Same author

COVID-19 confessions: a qualitative exploration of healthcare workers experiences of working with COVID-19.

BMJ open·2020
Same author

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.

BMC cancer·2020
Same author

Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale.

Thrombosis research·2020
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Area of Science:

  • Regenerative Medicine
  • Wound Healing Biology
  • Dermatology

Background:

  • Diabetic neuropathic ulcers and pressure ulcers represent significant clinical challenges.
  • Current treatments often yield suboptimal outcomes for these chronic wounds.
  • Platelet-derived growth factors play a crucial role in tissue repair and regeneration.

Purpose of the Study:

  • To evaluate the efficacy and safety of becaplermin (rh-PDGF-BB) for topical treatment of diabetic neuropathic and pressure ulcers.
  • To determine if becaplermin accelerates wound healing compared to placebo or standard care.
  • To assess the pharmacokinetic profile of topical becaplermin.

Main Methods:

  • Clinical trials involving patients with stage III/IV diabetic neuropathic ulcers and pressure ulcers.

Related Experiment Videos

  • Topical application of becaplermin (100 microg/g) once daily.
  • Comparison with placebo or standardized wound care protocols.
  • Assessment of complete healing rates and time to healing.

    • Main Results:

    • Becaplermin significantly increased complete ulcer healing rates and reduced healing time in diabetic neuropathic ulcers.
    • The therapy demonstrated superiority over placebo in patients with pressure sores.
    • Systemic absorption of becaplermin was minimal following topical administration.
    • Adverse event rates were comparable to placebo, with rash being the most common side effect.

    Conclusions:

    • Becaplermin is an effective topical treatment for promoting healing in diabetic neuropathic and pressure ulcers.
    • The growth factor enhances granulation tissue formation, cell migration, and proliferation.
    • Becaplermin offers a safe and well-tolerated therapeutic option for challenging wound types.